Can liver dysfunction change how tigecycline is metabolized and cleared?
Tigecycline is metabolized mainly by hepatic mechanisms, and liver dysfunction can change its exposure in the body. Clinical pharmacology information indicates that tigecycline clearance is reduced in people with impaired liver function, which can increase drug levels compared with those with normal hepatic function.
What do studies show in patients with impaired liver function?
In pharmacokinetic studies comparing people with different degrees of hepatic impairment to those with normal liver function, tigecycline exposure increases as liver function worsens, consistent with reduced systemic clearance. This means liver dysfunction can lead to higher concentrations for longer, even though tigecycline is primarily cleared through hepatic pathways rather than being cleared only by the kidneys.
Does impaired liver function require a dose adjustment?
Whether a dose adjustment is recommended depends on the specific prescribing guidance and the severity of liver impairment. The available pharmacokinetic findings support that exposure increases with impaired liver function, but dosing recommendations typically weigh the change in exposure against safety data.
How does this compare with kidney dysfunction?
Kidney impairment mainly affects drugs that rely heavily on renal excretion. Tigecycline’s exposure can still change in renal impairment, but the effect is generally not as dominant as the effect of hepatic impairment for clearance. The key point for your question is that liver dysfunction specifically can reduce hepatic clearance and raise tigecycline exposure.
What patients and clinicians should watch for?
Higher systemic exposure in liver dysfunction can increase the risk of tigecycline-related adverse effects. Clinicians commonly monitor for tolerability issues and avoid unnecessary accumulation by following the product’s liver-impairment guidance. If liver tests worsen during therapy, reassessing continuation and overall risk is standard practice.
Bottom line
Yes. Liver dysfunction can affect tigecycline’s hepatic clearance and metabolism, leading to higher tigecycline exposure in people with impaired liver function.
Sources: none provided in the prompt.